Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
4.070
+0.010 (0.25%)
At close: Nov 22, 2024, 4:00 PM
4.050
-0.020 (-0.49%)
After-hours: Nov 22, 2024, 7:38 PM EST
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for INO stock have an average target of 16.33, with a low estimate of 5.00 and a high estimate of 40. The average target predicts an increase of 301.23% from the current stock price of 4.07.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for INO stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $12 → $5 | Hold | Maintains | $12 → $5 | +22.85% | Nov 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $33 → $15 | Buy | Maintains | $33 → $15 | +268.55% | Nov 18, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +47.42% | Nov 15, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +71.99% | Oct 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $40 → $33 | Buy | Maintains | $40 → $33 | +710.81% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
329.43K
from 832.01K
Decreased by -60.41%
Revenue Next Year
202.00K
from 329.43K
Decreased by -38.68%
EPS This Year
-4.70
from -6.09
EPS Next Year
-3.74
from -4.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 525,000 | 525,000 | 26.1M | ||
| Avg | 329,432 | 202,000 | 16.7M | ||
| Low | 98,000 | n/a | 9.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -36.9% | 59.4% | 12,817.3% | ||
| Avg | -60.4% | -38.7% | 8,190.1% | ||
| Low | -88.2% | - | 4,721.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.48 | -2.89 | -1.86 | ||
| Avg | -4.70 | -3.74 | -2.76 | ||
| Low | -4.87 | -4.68 | -3.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.